Today: 8 June 2026
USB stock slips as U.S. Bancorp’s $1 billion BTIG deal puts Wall Street expansion back in view
13 January 2026
2 mins read

USB stock slips as U.S. Bancorp’s $1 billion BTIG deal puts Wall Street expansion back in view

New York, January 13, 2026, 10:14 EST — Regular session

  • U.S. Bancorp shares down about 1% after BTIG acquisition announcement
  • Deal values BTIG at up to $1 billion in cash and stock, with an earn-out component
  • Focus turns to U.S. Bancorp’s Jan. 20 earnings for details on capital and integration

U.S. Bancorp (USB) shares fell on Tuesday after the lender said it would buy Wall Street brokerage BTIG for up to $1 billion in cash and stock. The stock was down about 1% at $53.87, and Stephen Philipson called it “a strategic move to fill key product gaps” for corporate and institutional clients. Reuters

The deal is another step by a big regional lender toward businesses that live on fees rather than net interest margins. Those revenues can help in a strong market, but they tend to be less forgiving when equity issuance and dealmaking cool.

Investors will weigh whether the purchase adds durable growth without bringing the kind of volatility that comes with trading and underwriting. It also puts a spotlight back on costs and controls — the slow grind of integration matters more than the headline price.

U.S. Bancorp said it will pay a target $725 million at closing — $362.5 million in cash and about 6.6 million shares — with up to another $275 million in cash over three years tied to performance, an “earn-out” that lifts the total value to as much as $1 billion. The deal, signed on Jan. 12, is expected to close in the second quarter of 2026, subject to regulatory approvals, with BTIG’s leadership team staying on; U.S. Bancorp said it would have a negligible impact on 2026 earnings per share while trimming its Common Equity Tier 1 (CET1) ratio — a key measure of bank capital — by about 12 basis points (0.12%) at closing, without changing near-term capital return plans. U.S. Bancorp said its capital markets business generated about $1.4 billion in revenue in the 12 months through Sept. 30, 2025, and BTIG — its equity capital markets referral partner since 2014 — brings more than 700 employees in 20 cities and a history of more than 1,275 announced investment banking transactions since 2015, plus new capabilities in institutional equity sales and trading, electronic trading and M&A advisory (mergers and acquisitions); CEO Gunjan Kedia highlighted BTIG’s “top talent, capabilities and technology” and BTIG CEO Anton LeRoy said he was “thrilled to join U.S. Bancorp.” ir.usbank.com

The market did not give the bank much credit upfront. That may say less about BTIG than about timing: investors want proof the extra fee lines can hold up when markets turn and that cross-selling is real, not a slide-deck promise.

There are also obvious ways this could go sideways. A tougher regulatory review, a slowdown in equity underwriting, or simple culture clash could delay payoffs — and the earn-out means the final bill rises if BTIG hits targets while U.S. Bancorp still carries the integration work.

U.S. Bancorp is due to report fourth-quarter results before the market opens on Jan. 20. Kedia and CFO John Stern are scheduled to host a conference call at 8 a.m. CT, where investors are likely to push for more detail on costs, capital and how fast BTIG gets folded into the bank’s client coverage.

Between now and then, traders will watch for regulatory steps and any further disclosures that sharpen what the earn-out targets look like in practice.

Stock Market Today

  • How to Buy SpaceX Stock on Its IPO Day: Key Details for Investors
    June 8, 2026, 10:09 AM EDT. SpaceX is set to go public on Nasdaq on June 12, aiming to raise $75 billion in what would be the largest IPO ever. The IPO price is $135 per share, available mainly to select investors through brokers including Robinhood, SoFi, Charles Schwab, Fidelity, and E*TRADE. Public investors can buy shares under ticker SPCX when trading begins, using market orders for immediate purchase or limit orders to control price. However, acquiring IPO-priced shares isn't guaranteed and depends on broker rules and allocation. For those wary of direct investment risks in the high-reward space sector, exposure via exchange-traded funds (ETFs) with SpaceX holdings is an alternative option.

Latest articles

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

8 June 2026
Amazon’s new multibillion-dollar supply deal makes Corning a key fiber provider for U.S. data centers, but with shares up 305% in 12 months and investors already pricing in big AI wins, the stock was little changed at $177.58 premarket as risks of factory delays and high expectations loom.
BlackBerry Shares Stall After QNX Push

BlackBerry Stock Moves in Pre-Market Ahead of June Test

8 June 2026
BlackBerry’s U.S. shares rose 2.34% in premarket trading to $9.63 after Friday’s 8.99% drop, but with analyst targets averaging just $4.98, investors are betting on QNX growth and secure-communications wins ahead of June 25 earnings; any disappointment could hit the stock hard.
Micron Technology Stock Surges as AI Memory Shortage Puts MU at Center of Chip Rally

Micron Shares Edge Up in Premarket; Investors Await Next AI Test

8 June 2026
Micron surged 8.2% to $935.07 in Nasdaq premarket after Friday’s $127 billion rout, as investors cheered Nvidia’s confirmation it will keep sourcing high-bandwidth memory from Micron and Samsung, easing fears SK Hynix would become exclusive supplier; Cantor Fitzgerald raised its price target to $1,500, with Micron’s next earnings report due June 24.
Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

8 June 2026
Tango shares soared up to 48% in premarket trading after reporting a 92% objective response rate and 90% six-month progression-free survival in a 12-patient pancreatic cancer trial, with plans to advance the vopimetostat-daraxonrasib combo to Phase 3 testing in first-line MTAP-deleted pancreatic cancer.
Dow Jones today: DJIA slips from record as Visa and banks weigh after CPI
Previous Story

Dow Jones today: DJIA slips from record as Visa and banks weigh after CPI

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”
Next Story

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Go toTop